- Home
- ACB vs CCCC Comparison
ACB vs CCCC Comparison
Compare ACB & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- CCCC
- Stock Information
- Founded
- ACB 2013
- CCCC 2015
- Country
- ACB Canada
- CCCC United States
- Employees
- ACB N/A
- CCCC N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- CCCC Health Care
- Exchange
- ACB Nasdaq
- CCCC Nasdaq
- Market Cap
- ACB 313.9M
- CCCC 104.4M
- IPO Year
- ACB N/A
- CCCC 2020
- Fundamental
- Price
- ACB $4.43
- CCCC $1.52
- Analyst Decision
- ACB
- CCCC Buy
- Analyst Count
- ACB 0
- CCCC 3
- Target Price
- ACB N/A
- CCCC $12.00
- AVG Volume (30 Days)
- ACB 1.7M
- CCCC 1.4M
- Earning Date
- ACB 08-06-2025
- CCCC 07-31-2025
- Dividend Yield
- ACB N/A
- CCCC N/A
- EPS Growth
- ACB N/A
- CCCC N/A
- EPS
- ACB 0.03
- CCCC N/A
- Revenue
- ACB $238,837,444.00
- CCCC $39,783,000.00
- Revenue This Year
- ACB $12.22
- CCCC N/A
- Revenue Next Year
- ACB $7.36
- CCCC N/A
- P/E Ratio
- ACB $153.94
- CCCC N/A
- Revenue Growth
- ACB 27.32
- CCCC 98.56
- 52 Week Low
- ACB $3.42
- CCCC $1.09
- 52 Week High
- ACB $7.20
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- ACB 42.82
- CCCC 51.15
- Support Level
- ACB $3.91
- CCCC $1.36
- Resistance Level
- ACB $4.61
- CCCC $1.56
- Average True Range (ATR)
- ACB 0.27
- CCCC 0.12
- MACD
- ACB -0.04
- CCCC -0.00
- Stochastic Oscillator
- ACB 24.06
- CCCC 42.11
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.